Author

Shoji Oura

Observed names: Oura, Shoji, S Oura, S. Oura, S., Oura, Shoji OURA

Institution: Kishiwada Tokushukai Hospital

Observed institutions: Kansai Medical University, Wakayama Medical University, Kyorin University, Tokyo Metropolitan Komagome Hospital, Juntendo University, Shizuoka Cancer Center, Osaka National Hospital, Niigata Cancer Center Hospital, National Hospital Organization Kyushu Cancer Center, Okayama University Hospital, Kihoku hospital, Chiba Cancer Center, AntiCancer (United States), Kumamoto University Hospital, Kitakyushu Municipal Medical Center, Niigata University Medical and Dental Hospital, National Hospital Organization, Shikoku Cancer Center, Kishiwada Tokushukai Hospital, Juntendo University Hospital, Osaka International Cancer Institute, Japanese Foundation For Cancer Research, Rinku General Medical Center, Sagara Hospital, Wakayama Medical University Hospital, National Cancer Center Hospital, Aichi Cancer Center Hospital, The University of Tokyo, Wakayama University

ORCID: 0000-0003-0689-7958

Observed ORCID: 0000-0003-0689-7958

OpenAlex ID: A5039618762

Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size

2007 · Shoji Oura, Takeshi Tamaki, et al. · Breast Cancer · 138

Increased expression of integrin α3β1 in highly brain metastatic subclone of a human non‐small cell lung cancer cell line

2004 · Tatsuya Yoshimasu, Teruhisa Sakurai, et al. · Cancer Science · 70

PDF

Radiofrequency Ablation of Breast Cancer: A Retrospective Study

2017 · Toshikazu Ito, Shoji Oura, et al. · Clinical Breast Cancer · 69

PDF

Data acquisition for the histoculture drug response assay in lung cancer

2007 · Tatsuya Yoshimasu, Shoji Oura, et al. · Journal of Thoracic and Cardiovascular Surgery · 44

PDF

Expression of Bcl‐2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma

1999 · Qifeng Yang, Takeo Sakurai, et al. · Pathology International · 44

Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast‐conserving treatment after receiving neoadjuvant chemotherapy: Risk factors of IBTR and validation of the MD Anderson Prognostic Index

2012 · Makoto Ishitobi, Shozo Ohsumi, et al. · Cancer · 41

PDF

Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration

2020 · Yuka Aoishi, Shoji Oura, et al. · Breast Cancer · 39

Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.

2001 · H Tanino, S Oura, et al. · PubMed · 33

Fibroadenoma of the axillary accessory breast: diagnostic value of dynamic magnetic resonance imaging

2010 · Munehisa Sawa, Nobuyuki Kawai, et al. · Japanese Journal of Radiology · 31

Regression of a presumed meningioma with the antiestrogen agent mepitiostane

2000 · Shoji Oura, Takeo Sakurai, et al. · Journal of neurosurgery · 29

Surgical Treatment for Metachronous Second Primary Lung Cancer after Radical Resection of Primary Lung Cancer

2012 · Takahiko Ishigaki, Tatsuya Yoshimasu, et al. · Annals of Thoracic and Cardiovascular Surgery · 28

PDF

Limited mediastinal lymph node dissection for non-small cell lung cancer according to intraoperative histologic examinations

2005 · Tatsuya Yoshimasu, Shinichiro Miyoshi, et al. · Journal of Thoracic and Cardiovascular Surgery · 25

PDF

Accurate Pathological Prediction of Small Breast Cancer With Pathological Component-based Image Evaluation: A Case Report

2025 · Yurie Kitano, Shoji Oura, et al. · Cureus · 20

PDF

A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents.

2015 · Tatsuya Yoshimasu, Takuya Ohashi, et al. · PubMed · 20

[Malignancy-associated hypercalcemia].

2003 · Shoji Oura · PubMed · 20

Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer

2017 · Hiroji Iwata, Norikazu Masuda, et al. · Breast Cancer Research and Treatment · 17

In vitro evaluation of dose-response curve for paclitaxel in breast cancer

2007 · Tatsuya Yoshimasu, Shoji Oura, et al. · Breast Cancer · 17

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

2016 · Daigo Yamamoto, Nobuaki Sato, et al. · Breast Cancer Research and Treatment · 16

Histoculture drug response assay for gefitinib in non-small-cell lung cancer

2009 · Tatsuya Yoshimasu, Fuminori Ohta, et al. · General Thoracic and Cardiovascular Surgery · 16

Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung Cancer

2011 · Tatsuya Yoshimasu, Shoji Oura, et al. · Journal of Thoracic Oncology · 15

A Case of Diffuse Large B Cell Lymphoma of the Breast with Predominantly High-Level Internal Echoes

2020 · Masafumi Tomita, Shoji Oura, et al. · Case Reports in Oncology · 14

Quantitative Evaluation of Hormesis in Breast Cancer Using Histoculture Drug Response Assay

2019 · Yuka Aoishi, Tatsuya Yoshimasu, et al. · Dose-Response · 14

PDF

Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion

1999 · Xuefeng Jing, Kennichi Kakudo, et al. · Cancer · 14

PDF

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.

2015 · Takuya Ohashi, Tatsuya Yoshimasu, et al. · PubMed · 13

MR-axillography oriented surgical sampling for assessment of nodal status in the selection of patients with breast cancer for axillary lymph nodes dissection

2002 · Takaomi Suzuma, Takeo Sakurai, et al. · Breast Cancer · 12

Works count: 233

Citation count: 1,183

H-index: 17

I10-index: 31